Mesoblast (ASX:MSB) hits 300-patient enrolment in its Phase 3 chronic low back pain trial, setting up a mid-2027 readout on a US$10bn indication.
14
Stocks in Spotlight
View all →-
Growth Stocks · Financials Powerhouse Ventures (ASX:PVL) Merchant Model Delivers 22x and 240% Deal Wins July 15, 2026 -
AI Stocks · International Stocks SK hynix (NSDQ:SKHY) Surges 27% as Investors Reprice Its 58% HBM Leadership July 15, 2026 -
Financials · Growth Stocks Powerhouse Ventures (ASX:PVL) Builds a Merchant Revenue Engine as CIO Fund Scales July 3, 2026
